Gemcitabine (GEM)

DRUG12 trials

Conditions

Advanced Pancreatic CarcinomaCarboplatinCarcinoma in Situ of BladderCarcinoma, Transitional CellDocetaxelExtranodal NK/T-cell LymphomaGemcitabineKRAS P.G12C

Phase 1

Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer

WithdrawnNCT05251038

Devalingam MahalingamKRAS P.G12C, Metastatic Pancreatic Cancer, Pancreatic Cancer +1

Start: 2022-09-13End: 2023-01-31Updated: 2023-05-11

HCW9218 for Advanced Pancreatic Cancer

CompletedNCT05304936

ImmunityBio, Inc.Advanced Pancreatic Carcinoma

Start: 2022-10-17End: 2025-02-15Updated: 2026-04-15

A Study of MR001 Combined With Chemotherapy in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) After First-line Therapy

RecruitingNCT07235202

Shenzhen Majory Biotechnology Co., Ltd.Pancreatic Ductal Adenocarcinoma (PDAC)

Start: 2025-12-24End: 2028-12-22Target: 45Updated: 2026-05-26

Phase 2

Neoadjuvant Chemotherapy Plus Toripalimab in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma

Active, not recruitingNCT05813626

Zhejiang Cancer HospitalNasopharyngeal Carcinoma

Start: 2023-04-21End: 2027-10-30Target: 89Updated: 2026-07-10

Perioperative Chemotherapy and Immunotherapy for Locally Recurrent Nasopharyngeal Carcinoma

Not yet recruitingNCT07129772

The University of Hong KongNasopharyngeal Cancer Recurrent, Nasopharyngeal Cancinoma (NPC)

Start: 2025-11-01End: 2028-06-30Target: 53Updated: 2025-09-04

Toripalimab ± Sequential Intravesical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk NMIBC: Open-Label Randomized Phase 2 Study

Not yet recruitingNCT07189793

First Affiliated Hospital of Wenzhou Medical UniversityCarcinoma in Situ of Bladder, Carcinoma, Transitional Cell, Non-Muscle-Invasive Bladder Cancer +1

Start: 2025-10-31End: 2028-10-31Target: 106Updated: 2025-09-24

Selinexor Combined With Reduced-Dose Radiotherapy For Early-Stage Extranodal NK/T-Cell Lymphoma

Not yet recruitingNCT07554482

Beijing Tongren HospitalExtranodal NK/T-cell Lymphoma

Start: 2026-05-15End: 2029-04-30Target: 34Updated: 2026-04-28

Phase 3

A Study of FG-M108+Chemotherapy vs Placebo+Chemotherapy in Claudin18.2-positive Pancreatic Cancer

Not yet recruitingNCT07383922

FutureGen Biopharmaceutical (Beijing) Co., LtdPancreatic Cancer

Start: 2026-02-28End: 2030-12-31Target: 524Updated: 2026-02-04

Anlotinib Plus Immunotherapy and Chemoradiotherapy for High-Risk Nasopharyngeal Carcinoma

Not yet recruitingNCT07385079

Sun Yat-sen UniversityNasopharyngeal Cancer, Nasopharyngeal Cancinoma (NPC)

Start: 2026-03-01End: 2030-01-01Target: 412Updated: 2026-02-03

Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC

RecruitingNCT07459296

First Affiliated Hospital of Guangxi Medical UniversityNasopharyngeal Carcinoma (NPC)

Start: 2026-03-05End: 2032-04-01Target: 266Updated: 2026-03-16

Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )

RecruitingNCT07621718

Revolution Medicines, Inc.Pancreatic Adenocarcinoma, Pancreatic Adenocarcinoma Metastatic, Pancreatic Adenosquamous Carcinoma +5

Start: 2026-05-22End: 2030-04-22Target: 670Updated: 2026-07-08

Unknown Phase

Prospective Observational Study of Outcomes After Gemcitabine, Docetaxel, Melphalan, and Carboplatin With Autologous Stem Cell Transplantation in Pediatric Relapsed/Refractory Germ Cell Tumors

RecruitingNCT07662018

M.D. Anderson Cancer CenterCarboplatin, Docetaxel, Gemcitabine +5

Start: 2026-06-05End: 2033-12-31Target: 30Updated: 2026-06-23

Related Papers

Abstract 4441: Bifunctional immunotherapeutic HCW9218 facilitates recruitment of immune cells from tumor draining lymph nodes to promote antitumor activity and enhance checkpoint blockade efficacy in solid tumors

Cancer Research2023-04-042 citations